Consun Pharmaceutical Group Limited

SEHK:1681 Stock Report

Market Cap: HK$6.4b

Consun Pharmaceutical Group Future Growth

Future criteria checks 4/6

Consun Pharmaceutical Group is forecast to grow earnings and revenue by 14.7% and 13.3% per annum respectively. EPS is expected to grow by 14.1% per annum. Return on equity is forecast to be 23.8% in 3 years.

Key information

14.7%

Earnings growth rate

14.1%

EPS growth rate

Pharmaceuticals earnings growth11.0%
Revenue growth rate13.3%
Future return on equity23.8%
Analyst coverage

Low

Last updated22 Nov 2024

Recent future growth updates

No updates

Recent updates

These 4 Measures Indicate That Consun Pharmaceutical Group (HKG:1681) Is Using Debt Safely

Nov 27
These 4 Measures Indicate That Consun Pharmaceutical Group (HKG:1681) Is Using Debt Safely

Consun Pharmaceutical Group Limited's (HKG:1681) Shares Leap 32% Yet They're Still Not Telling The Full Story

Oct 02
Consun Pharmaceutical Group Limited's (HKG:1681) Shares Leap 32% Yet They're Still Not Telling The Full Story

Here's Why Consun Pharmaceutical Group (HKG:1681) Has Caught The Eye Of Investors

Sep 26
Here's Why Consun Pharmaceutical Group (HKG:1681) Has Caught The Eye Of Investors

Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet

Jun 12
Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet

Consun Pharmaceutical Group's (HKG:1681) Dividend Will Be CN¥0.30

May 12
Consun Pharmaceutical Group's (HKG:1681) Dividend Will Be CN¥0.30

Consun Pharmaceutical Group (HKG:1681) Is Increasing Its Dividend To CN¥0.30

Jun 01
Consun Pharmaceutical Group (HKG:1681) Is Increasing Its Dividend To CN¥0.30

Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet

May 04
Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet

Consun Pharmaceutical Group (HKG:1681) Will Pay A Dividend Of HK$0.20

Apr 28
Consun Pharmaceutical Group (HKG:1681) Will Pay A Dividend Of HK$0.20

Consun Pharmaceutical Group (HKG:1681) Has Announced A Dividend Of HK$0.20

Apr 07
Consun Pharmaceutical Group (HKG:1681) Has Announced A Dividend Of HK$0.20

Consun Pharmaceutical Group (HKG:1681) Has Announced That It Will Be Increasing Its Dividend To HK$0.10

Aug 26
Consun Pharmaceutical Group (HKG:1681) Has Announced That It Will Be Increasing Its Dividend To HK$0.10

Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Rather Sparingly

Apr 21
Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Rather Sparingly

Does It Make Sense To Buy Consun Pharmaceutical Group Limited (HKG:1681) For Its Yield?

Mar 17
Does It Make Sense To Buy Consun Pharmaceutical Group Limited (HKG:1681) For Its Yield?

Here's Why Consun Pharmaceutical Group's (HKG:1681) Statutory Earnings Are Arguably Too Conservative

Feb 19
Here's Why Consun Pharmaceutical Group's (HKG:1681) Statutory Earnings Are Arguably Too Conservative

How Much Did Consun Pharmaceutical Group's(HKG:1681) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 29
How Much Did Consun Pharmaceutical Group's(HKG:1681) Shareholders Earn From Share Price Movements Over The Last Three Years?

Could The Consun Pharmaceutical Group Limited (HKG:1681) Ownership Structure Tell Us Something Useful?

Jan 08
Could The Consun Pharmaceutical Group Limited (HKG:1681) Ownership Structure Tell Us Something Useful?

Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Quite Sensibly

Dec 18
Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Quite Sensibly

Should Consun Pharmaceutical Group Limited (HKG:1681) Be Part Of Your Income Portfolio?

Nov 18
Should Consun Pharmaceutical Group Limited (HKG:1681) Be Part Of Your Income Portfolio?

Earnings and Revenue Growth Forecasts

SEHK:1681 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20263,8321,213N/A1,2492
12/31/20253,2991,0196991,0323
12/31/20242,9298966579053
6/30/20242,739836833915N/A
3/31/20242,665810800867N/A
12/31/20232,590785766819N/A
9/30/20232,528759797844N/A
6/30/20232,466734828869N/A
3/31/20232,403708862908N/A
12/31/20222,340683896948N/A
9/30/20222,246660836906N/A
6/30/20222,152636776865N/A
3/31/20222,098613701795N/A
12/31/20212,045590627726N/A
9/30/20211,959565655731N/A
6/30/20211,874541683737N/A
3/31/20211,813520748802N/A
12/31/20201,753499813867N/A
9/30/20201,653269639717N/A
6/30/20201,55339465567N/A
3/31/20201,64160334475N/A
12/31/20191,72880203383N/A
9/30/20191,822288231442N/A
6/30/20191,916496259501N/A
3/31/20191,880481410628N/A
12/31/20181,844465561754N/A
9/30/20181,802448519662N/A
6/30/20181,760430476570N/A
3/31/20181,710413N/A411N/A
12/31/20171,660396N/A252N/A
9/30/20171,601372N/A323N/A
6/30/20171,541347N/A393N/A
3/31/20171,382327N/A421N/A
12/31/20161,223308N/A449N/A
9/30/20161,060291N/A362N/A
6/30/2016896274N/A275N/A
3/31/2016863262N/A230N/A
12/31/2015831250N/A184N/A
9/30/2015814246N/A180N/A
6/30/2015798242N/A175N/A
3/31/2015764226N/A235N/A
12/31/2014731211N/A295N/A
9/30/2014697198N/A285N/A
6/30/2014664185N/A275N/A
3/31/2014618169N/A219N/A
12/31/2013572153N/A164N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1681's forecast earnings growth (14.7% per year) is above the savings rate (2.3%).

Earnings vs Market: 1681's earnings (14.7% per year) are forecast to grow faster than the Hong Kong market (11.5% per year).

High Growth Earnings: 1681's earnings are forecast to grow, but not significantly.

Revenue vs Market: 1681's revenue (13.3% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).

High Growth Revenue: 1681's revenue (13.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 1681's Return on Equity is forecast to be high in 3 years time (23.8%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 16:54
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Consun Pharmaceutical Group Limited is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Fangqi DaiChina Merchants Securities (HK) Co., Ltd
null nullCMB International Securities Limited
Trina ChenCredit Suisse